Open AccessP1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH‐222, A NOVEL CD22‐TARGETING ANTIBODY‐DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (R/R NHL)
Author(s) -
HernandezIlizaliturri F. J.,
Kuruvilla J.,
Christian B. A.,
Flinn I. W.,
Assouline S. E.,
Ulrickson M. L.,
Landsburg D. J.,
Stuart M.,
Lowman H.,
Levin N.,
Maetzel D.,
Viller N. N.,
MacLaren A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847476.69621.cd
Subject(s) - medicine , tolerability , pharmacokinetics , antibody drug conjugate , cmax , refractory (planetary science) , phases of clinical research , gastroenterology , lymphoma , oncology , antibody , pharmacology , toxicity , adverse effect , monoclonal antibody , immunology , physics , astrobiology